News | January 02, 2014

Medtronic Randomizes First Patients in Symplicity HTN-4

Clinical trial could expand access to Symplicity renal denervation system

medtronic symplicity renal denervation therapy hypertension cath lab trial study

January 2, 2014 — Medtronic Inc. announced that the first patients were randomized in Symplicity HTN-4, which will evaluate the Symplicity renal denervation system in patients with moderate uncontrolled hypertension (systolic blood pressure greater than or equal to 140 and less than 160 mm Hg, despite treatment with three or more anti-hypertensive medications of different classes). Symplicity HTN-4, which randomized its first patients at Medical University of South Carolina (MUSC), Piedmont Heart Institute and Duke University Medical Center, builds upon Symplicity HTN-3, the only other renal denervation clinical trial in the United States. In the United States, the Symplicity renal denervation system is available for investigational use only.
 
Symplicity HTN-4 will enroll up to 580 patients at approximately 100 sites, continuing to target a patient population in line with the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7), the American Heart Association (AHA) and the European Society of Hypertension's definition of uncontrolled hypertension. Similar to the U.S. trial, Symplicity HTN-3 study evaluating patients with uncontrolled hypertension with a systolic blood pressure greater than or equal to 160 mm Hg, the Symplicity HTN-4 study will be blinded and include a sham control.
 
Principal investigators of Symplicity HTN-4 are David Kandzari, M.D., director and chief scientific officer, Interventional Cardiology and Interventional Cardiology Research, Piedmont Heart Institute, Atlanta, and Michael Weber, M.D., professor of medicine, Division of Cardiovascular Medicine, SUNY Downstate College of Medicine, Brooklyn, New York City.
 
For more information: www.symplifybptrial.com, www.medtronicrdn.com

Related Content

News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
News | Cardiovascular Clinical Studies

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
News | Cardiovascular Clinical Studies

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
News | Cardiovascular Clinical Studies

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
News | Cardiovascular Clinical Studies

November 6, 2023 — Bristol Myers Squibb announced that research across the company’s cardiovascular franchise will be ...

Home November 06, 2023
Home
News | Cardiovascular Clinical Studies

October 20, 2023 — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) ...

Home October 20, 2023
Home
News | Cardiovascular Clinical Studies

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home October 12, 2023
Home
Subscribe Now